In parallel, ACSL1 low-expression subgroup in ccRCC, which is marked by high immune infiltration and immune checkpoint expression, and may respond better to a combination of multiple immune checkpoint inhibitors. The gene discussed is ACSL1; the disease is nonpapillary renal cell carcinoma.